Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands

Fig. 3

Discounted net costs and quality-adjusted life years gained of various pneumococcal vaccination strategies (indicated in colors) compared to no vaccination (x = 0, y = 0) in older adults, while varying the childhood vaccine (indicated by the symbols). Results are presented for a 65-year-old cohort with a vaccination coverage of 70%, followed for 15 years. For PCV21, we assumed that the vaccine price was equal to PCV20. 3xPPV23: PPV23 administered at years 0, 5, and 10; PCV15 + 3xPPV23: PCV15 administered at year 0 and PPV23 at years 1, 6, and 11; PCV20 + 3xPPV23: PCV20 administered at year 0 and PPV23 at years 1, 6, and 11. PCV, pneumococcal conjugate vaccine; PPV, pneumococcal polysaccharide vaccine; QALY, quality-adjusted life year

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us